OmniGuide’s RevoLix HTL Hybrid Thulium Laser OK’ed for BPH and Stone Treatments

OmniGuide Holdings has received U.S. Food and Drug Administration (FDA) clearance for its RevoLix HTL family of pulsed and continuous wave Thulium YAG lasers for benign prostatic hyperplasia (BPH) and stone management procedures in urologic patients.
 
“The FDA’s clearance reflects our confidence in our unique RevoLix HTL therapy and our efforts into surgical laser innovation, setting new standards in patients’ safety,” Dr. Samir Lamrini, global director of R&D of LISA Institute for Digital Surgery, told the press. “We believe strongly in our patient first innovation mindset, setting a path forward for urology patients to receive therapy for both BPH and Stone Management.”
 
“RevoLix HTL innovative Thulium YAG Continuous Wave and Pulse modes allow complete surgical customization of the Therapy parameters providing the surgeon with full control and confidence to address any Urological clinical procedure,” said Giorgio Brusa, OmniGuide’s exec. VP of global marketing. “Virtually no stone retropulsion and superior stone dusting compared to the gold standard Holmium YAG decreases OR time and may lead to improved patient outcomes. At the same time, patent pending HTL technology allows for stone clearance without overheating stone and urine medium.”
 
“With over 600 peer reviewed clinical articles and 31 years of surgical Thulium laser research and development experience, RevoLix and OmniGuide look forward to serving patients and their Urologist here in the United States,” said Carlos Acosta, OmniGuide’s global director of RA QA. “With 2,500 lasers and over 200,000 patients per year treated globally by LISA Thulium technology , the RevoLix product family has demonstrated a long clinical history of patient safety and low patient complication rate.”